These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

59 related articles for article (PubMed ID: 24648585)

  • 1. Interferon Therapy in Myelofibrosis: Systematic Review and Meta-analysis.
    Bewersdorf JP; Giri S; Wang R; Podoltsev N; Williams RT; Rampal RK; Tallman MS; Zeidan AM; Stahl M
    Clin Lymphoma Myeloma Leuk; 2020 Oct; 20(10):e712-e723. PubMed ID: 32669244
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Erratum. A survival analysis of ventricular access devices for delivery of cerliponase alfa.
    Craven CL
    J Neurosurg Pediatr; 2022 Jul; 30(1):132. PubMed ID: 35561691
    [No Abstract]   [Full Text] [Related]  

  • 3. Interferon for interferon nonresponding and relapsing patients with chronic hepatitis C.
    Koretz RL; Pleguezuelo M; Arvaniti V; Barrera Baena P; Ciria R; Gurusamy KS; Davidson BR; Burroughs AK
    Cochrane Database Syst Rev; 2013 Jan; 2013(1):CD003617. PubMed ID: 23440791
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Interferon alfa versus interferon alfa plus cytarabine combination therapy for chronic myeloid leukemia: a meta-analysis of randomized controlled trials.
    Chen R; Ma B; Yang K; Tian J; Liu Y; Zhao L
    Curr Ther Res Clin Exp; 2011 Aug; 72(4):150-63. PubMed ID: 24648585
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment of Philadelphia chromosome-positive early chronic phase chronic myelogenous leukemia with daily doses of interferon alpha and low-dose cytarabine.
    Kantarjian HM; O'Brien S; Smith TL; Rios MB; Cortes J; Beran M; Koller C; Giles FJ; Andreeff M; Kornblau S; Giralt S; Keating MJ; Talpaz M
    J Clin Oncol; 1999 Jan; 17(1):284-92. PubMed ID: 10458244
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Alpha-interferon in combination with cytarabine in children with Philadelphia chromosome-positive chronic myeloid leukemia.
    Millot F; Brice P; Philippe N; Thyss A; Demeoq F; Wetterwald M; Boccara JF; Vilque JP; Guyotat D; Guilhot J; Guilhot F
    J Pediatr Hematol Oncol; 2002 Jan; 24(1):18-22. PubMed ID: 11902732
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Adefovir dipivoxil and pegylated interferon alfa-2a for the treatment of chronic hepatitis B: a systematic review and economic evaluation.
    Shepherd J; Jones J; Takeda A; Davidson P; Price A
    Health Technol Assess; 2006 Aug; 10(28):iii-iv, xi-xiv, 1-183. PubMed ID: 16904047
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Interferon alfa-2b combined with cytarabine versus interferon alone in chronic myelogenous leukemia. French Chronic Myeloid Leukemia Study Group.
    Guilhot F; Chastang C; Michallet M; Guerci A; Harousseau JL; Maloisel F; Bouabdallah R; Guyotat D; Cheron N; Nicolini F; Abgrall JF; Tanzer J
    N Engl J Med; 1997 Jul; 337(4):223-9. PubMed ID: 9227927
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Interferon alpha plus intermittent oral Ara-C ocfosfate (YNK-01) in chronic myeloid leukemia primarily resistant or with minimal cytogenetic response to interferon.
    Cervantes F; Sureda A; Hernández-Boluda JC; Martino R; Brunet S; Borrego D; Antich JL; Montserrat E
    Haematologica; 2001 Dec; 86(12):1281-6. PubMed ID: 11726320
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Survival outcomes for clonal evolution in chronic myeloid leukemia patients on second generation tyrosine kinase inhibitor therapy.
    Verma D; Kantarjian H; Shan J; O'Brien S; Estrov Z; Garcia-Manero G; Koller C; Borthakur G; Cortes J
    Cancer; 2010 Jun; 116(11):2673-81. PubMed ID: 20499401
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Optimizing therapy for patients with chronic myelogenous leukemia in chronic phase.
    Kantarjian HM; Cortes J; La Rosée P; Hochhaus A
    Cancer; 2010 Mar; 116(6):1419-30. PubMed ID: 20120030
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Epidemiology of chronic myeloid leukaemia (CML).
    Rohrbacher M; Hasford J
    Best Pract Res Clin Haematol; 2009 Sep; 22(3):295-302. PubMed ID: 19959081
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A phase II study of continuous infusion homoharringtonine and cytarabine in newly diagnosed patients with chronic myeloid leukemia: CALGB study 19804.
    Stone RM; Donohue KA; Stock W; Hars V; Linker CA; Shea T; Deangelo DJ; Marcucci G; Bloomfield CD; Larson RA;
    Cancer Chemother Pharmacol; 2009 Apr; 63(5):859-64. PubMed ID: 18670778
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Imatinib for newly diagnosed patients with chronic myeloid leukemia: incidence of sustained responses in an intention-to-treat analysis.
    de Lavallade H; Apperley JF; Khorashad JS; Milojkovic D; Reid AG; Bua M; Szydlo R; Olavarria E; Kaeda J; Goldman JM; Marin D
    J Clin Oncol; 2008 Jul; 26(20):3358-63. PubMed ID: 18519952
    [TBL] [Abstract][Full Text] [Related]  

  • 15.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 16.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 17.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 18.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 19.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 3.